Join Alterity Therapeutics for a virtual key opinion leader (KOL) event featuring Roy Freeman, MD (Harvard Medical School, Beth Israel Deaconess Medical Center) and Daniel Claassen, MD, MS (Vanderbilt University Medical Center), alongside David Stamler, MD, (CEO, Alterity Therapeutics), to discuss the significant unmet need and current treatment landscape in Multiple System Atrophy (MSA), a rare, rapidly progressive neurodegenerative disease with no approved treatment, and the opportunity for ATH434, a novel, potential first-in-class investigational agent in late-stage clinical development.

Previously presented Phase 2 data demonstrated up to 48% slowing of disease progression versus placebo with a favorable safety profile.

Event Highlights to Include:

• ATH434 Overview: Alterity’s lead candidate and a potential first-in-class, disease-modifying therapy for MSA
• MSA Background: Disease overview and review of therapeutic options
• Phase 2 Program: Review Phase 2 data, including new insights and analyses
• Phase 3 Planning: High level overview of the planned Phase 3 program

A live question and answer session will follow the formal presentations.